The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Myeloid-Derived Suppressor Cells Suppress Antitumor Immune Responses through IDO Expression and Correlate with Lymph Node Metastasis in Patients with Breast Cancer
Abstract
Myeloid-derived suppressor cells (MDSCs) represent heterogeneous immunosuppressive cells in multiple cancer types and display potent immunosuppressive activity on T cells. We have shown the increased expression of IDO in breast cancer. Because IDO plays a pivotal role in immune tolerance via suppressing T cell function, the aim of this study was to investigate the expression of IDO in MDSCs in breast cancer and its role in MDSC-mediated inhibition of immune surveillance. The proportion of MDSCs with the phenotype of CD45+CD13+CD33+CD14−CD15− significantly increased in primary cancer tissues and patients’ peripheral blood. IDO expression was significantly upregulated in MDSCs isolated from fresh breast cancer tissues (fresh MDSCs [fMDSCs]), which correlated with increased infiltration of Foxp3+ regulatory T cells in tumors and lymph node metastasis in patients. fMDSCs inhibited IL-2 and anti-CD3/CD28 mAb-induced T cell amplification and Th1 polarization but stimulated apoptosis in T cells in an IDO-dependent manner. CD33+ progenitors isolated from healthy donors’ umbilical cord blood were cocultured with breast cancer cell line MDA-MB-231 cells to induce MDSCs. IDO expression was upregulated in induced MDSCs, which required phosphorylation of STAT3, but not STAT1. IDO was required for induced MDSCs’ immunosuppressive activity on T cells, which was blocked by IDO inhibitor 1-methyl-l-tryptophan or STAT3 antagonist JSI-124. Consistently, increased STAT3 phosphorylation level was found in fMDSCs. Together, our findings suggest that STAT3-dependent IDO expression mediates immunosuppressive effects of MDSCs in breast cancer. Thus, inhibition of MDSC-induced T cell suppression by blocking IDO may represent a previously unrecognized mechanism underlying immunotherapy for breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer
Watkins, S. K., Zhu, Z., Riboldi, E., Shafer-Weaver, K., Stagliano, K. E., Sklavos, M. M., Ambs, S., Yagita∥, H., & Hurwitz, A. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44325 · Cited by 137
RetractedCoussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544
Ido expression by dendritic cells: tolerance and tryptophan catabolism
Mellor, A. L., & Munn, D. H. (2004) · Nature Reviews Immunology · doi:10.1038/nri1457 · Cited by 2,341
Uyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305
Almand, B., Clark, J. I., Nikitina, E., van Beynen, J., English, N. R., Knight, S. C., Carbone, D. P., & Gabrilovich, D. I. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.1.678 · Cited by 1,337
Munn, D. H., Sharma, M. D., Baban, B., Harding, H. P., Zhang, Y., Ron, D., & Mellor, A. L. (2005) · Immunity · doi:10.1016/j.immuni.2005.03.013 · Cited by 1,272
Corzo, C. A., Condamine, T., Lu, L., Cotter, M. J., Youn, J.-I., Cheng, P., Cho, H.-I., Celis, E., Quiceno, D. G., Padhya, T., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100587 · Cited by 1,173
Suzuki, E., Kapoor, V., Jassar, A. S., Kaiser, L. R., & Albelda, S. M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0883 · Cited by 1,054
Cited by
The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
Kumar, V., Patel, S., Tcyganov, E., & Gabrilovich, D. I. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.01.004 · Cited by 2,008
Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity
Veglia, F., Sanseviero, E., & Gabrilovich, D. I. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-020-00490-y · Cited by 1,940
Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape
Jiang, X., Wang, J., Deng, X., Xiong, F., Ge, J., Xiang, B., Wu, X., Ma, J., Zhou, M., Li, X., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-018-0928-4 · Cited by 1,457
Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected
Marvel, D., & Gabrilovich, D. I. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80005 · Cited by 1,050
IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance
Munn, D. H., & Mellor, A. L. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.01.002 · Cited by 1,041
Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer
Li, K., Shi, H., Zhang, B., Ou, X., Ma, Q., Chen, Y., Shu, P., Li, D., & Wang, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00670-9 · Cited by 988
Self-citationCell Adhesion Molecules and Their Roles and Regulation in the Immune and Tumor Microenvironment
Harjunpää, H., Llort Asens, M., Guenther, C., & Fagerholm, S. C. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01078 · Cited by 764
The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses
Labani-Motlagh, A., Ashja-Mahdavi, M., & Loskog, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00940 · Cited by 751
Tumor-associated stromal cells as key contributors to the tumor microenvironment
Bussard, K. M., Mutkus, L., Stumpf, K., Gomez-Manzano, C., & Marini, F. C. (2016) · Breast Cancer Research · doi:10.1186/s13058-016-0740-2 · Cited by 746
The CXCL8-CXCR1/2 pathways in cancer
Liu, Q., Li, A., Tian, Y., Wu, J. D., Liu, Y., Li, T., Chen, Y., Han, X., & Wu, K. (2016) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2016.08.002 · Cited by 662
Ugel, S., De Sanctis, F., Mandruzzato, S., & Bronte, V. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80006 · Cited by 559
Epigenetic therapy in immune-oncology
Jones, P. A., Ohtani, H., Chakravarthy, A., & De Carvalho, D. D. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0109-9 · Cited by 550
Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy
Kishton, R. J., Sukumar, M., & Restifo, N. P. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.06.016 · Cited by 548
Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors
Weber, R., Fleming, V., Hu, X., Nagibin, V., Groth, C., Altevogt, P., Utikal, J., & Umansky, V. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01310 · Cited by 538
Regulation of Tumor Metastasis by Myeloid-Derived Suppressor Cells
Condamine, T., Ramachandran, I., Youn, J.-I., & Gabrilovich, D. I. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-051013-052304 · Cited by 521
Myeloid-derived suppressor cells in cancer and cancer therapy
Lasser, S. A., Ozbay Kurt, F. G., Arkhypov, I., Utikal, J., & Umansky, V. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00846-y · Cited by 489
Myeloid-Derived Suppressor Cells
(2015) · Advances in Cancer Research · doi:10.1016/bs.acr.2015.04.002 · Cited by 482
Oh, M.-H., Sun, I.-H., Zhao, L., Leone, R. D., Sun, I.-M., Xu, W., Collins, S. L., Tam, A. J., Blosser, R. L., Patel, C. H., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci131859 · Cited by 456
Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer
Law, A. M. K., Valdes-Mora, F., & Gallego-Ortega, D. (2020) · Cells · doi:10.3390/cells9030561 · Cited by 455
Targeting the IDO1 pathway in cancer: from bench to bedside
Liu, M., Wang, X., Wang, L., Ma, X., Gong, Z., Zhang, S., & Li, Y. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0644-y · Cited by 447
Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype
Gabrusiewicz, K., Rodriguez, B., Wei, J., Hashimoto, Y., Healy, L. M., Maiti, S. N., Thomas, G., Zhou, S., Wang, Q., Elakkad, A., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.85841 · Cited by 445
IDO1 in cancer: a Gemini of immune checkpoints
Zhai, L., Ladomersky, E., Lenzen, A., Nguyen, B., Patel, R., Lauing, K. L., Wu, M., & Wainwright, D. A. (2018) · Cellular & Molecular Immunology · doi:10.1038/cmi.2017.143 · Cited by 437
The Multifaceted Roles Neutrophils Play in the Tumor Microenvironment
Sionov, R. V., Fridlender, Z. G., & Granot, Z. (2015) · Cancer Microenvironment · doi:10.1007/s12307-014-0147-5 · Cited by 416
T Cell Dysfunction and Exhaustion in Cancer
Zhang, Z., Liu, S., Zhang, B., Qiao, L., Zhang, Y., & Zhang, Y. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00017 · Cited by 385
The IL-8/IL-8R Axis: A Double Agent in Tumor Immune Resistance
David, J., Dominguez, C., Hamilton, D., & Palena, C. (2016) · Vaccines · doi:10.3390/vaccines4030022 · Cited by 395
Lin, H., Liu, C., Hu, A., Zhang, D., Yang, H., & Mao, Y. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01544-7 · Cited by 392
Cancer prevention and therapy through the modulation of the tumor microenvironment
Casey, S. C., Amedei, A., Aquilano, K., Azmi, A. S., Benencia, F., Bhakta, D., Bilsland, A. E., Boosani, C. S., Chen, S., Ciriolo, M. R., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.02.007 · Cited by 372
Yang, L., Chu, Z., Liu, M., Zou, Q., Li, J., Liu, Q., Wang, Y., Wang, T., Xiang, J., & Wang, B. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01453-1 · Cited by 352
Self-citationMetabolic communication in the tumour–immune microenvironment
Kao, K.-C., Vilbois, S., Tsai, C.-H., & Ho, P.-C. (2022) · Nature Cell Biology · doi:10.1038/s41556-022-01002-x · Cited by 349
Flores-Toro, J. A., Luo, D., Gopinath, A., Sarkisian, M. R., Campbell, J. J., Charo, I. F., Singh, R., Schall, T. J., Datta, M., Jain, R. K., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1910856117 · Cited by 334
De Cicco, P., Ercolano, G., & Ianaro, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01680 · Cited by 332
Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axis
Waight, J. D., Netherby, C., Hensen, M. L., Miller, A., Hu, Q., Liu, S., Bogner, P. N., Farren, M. R., Lee, K. P., Liu, K., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68189 · Cited by 323
Ninomiya, S., Narala, N., Huye, L., Yagyu, S., Savoldo, B., Dotti, G., Heslop, H. E., Brenner, M. K., Rooney, C. M., & Ramos, C. A. (2015) · Blood · doi:10.1182/blood-2015-01-621474 · Cited by 315
CCL2/CCR2 signaling in cancer pathogenesis
Hao, Q., Vadgama, J. V., & Wang, P. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-00589-8 · Cited by 315
IL-6 as a major regulator of MDSC activity and possible target for cancer immunotherapy
Weber, R., Groth, C., Lasser, S., Arkhypov, I., Petrova, V., Altevogt, P., Utikal, J., & Umansky, V. (2021) · Cellular Immunology · doi:10.1016/j.cellimm.2020.104254 · Cited by 309
The therapeutic potential of targeting tryptophan catabolism in cancer
Opitz, C. A., Somarribas Patterson, L. F., Mohapatra, S. R., Dewi, D. L., Sadik, A., Platten, M., & Trump, S. (2020) · British Journal of Cancer · doi:10.1038/s41416-019-0664-6 · Cited by 300
Yang, Y., Li, C., Liu, T., Dai, X., & Bazhin, A. V. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01371 · Cited by 291
Multiple Sclerosis: Immunopathology and Treatment Update
Dargahi, N., Katsara, M., Tselios, T., Androutsou, M.-E., De Courten, M., Matsoukas, J., & Apostolopoulos, V. (2017) · Brain Sciences · doi:10.3390/brainsci7070078 · Cited by 285
STAT proteins in cancer: orchestration of metabolism
Li, Y.-J., Zhang, C., Martincuks, A., Herrmann, A., & Yu, H. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00537-3 · Cited by 282
Zhang, H., Ye, Y.-L., Li, M.-X., Ye, S.-B., Huang, W.-R., Cai, T.-T., He, J., Peng, J.-Y., Duan, T.-H., Cui, J., et al. (2017) · Oncogene · doi:10.1038/onc.2016.367 · Cited by 278
Indoleamine 2,3-Dioxygenase and Its Therapeutic Inhibition in Cancer
(2018) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2017.07.004 · Cited by 270
GM-CSF: A Double-Edged Sword in Cancer Immunotherapy
Kumar, A., Taghi Khani, A., Sanchez Ortiz, A., & Swaminathan, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.901277 · Cited by 265
The untold story of IFN-γ in cancer biology
Kursunel, M. A., & Esendagli, G. (2016) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2016.07.005 · Cited by 192
Michaeli, J., Shaul, M. E., Mishalian, I., Hovav, A.-H., Levy, L., Zolotriov, L., Granot, Z., & Fridlender, Z. G. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1356965 · Cited by 159
STAT3, a master regulator of anti-tumor immune response
Rébé, C., & Ghiringhelli, F. (2019) · Cancers · doi:10.3390/cancers11091280 · Cited by 129
Zoso, A., Mazza, E. M. C., Bicciato, S., Mandruzzato, S., Bronte, V., Serafini, P., & Inverardi, L. (2014) · European Journal of Immunology · doi:10.1002/eji.201444522 · Cited by 123
Immunotherapy in breast cancer: Current status and future directions
(2019) · Advances in Cancer Research · doi:10.1016/bs.acr.2019.03.006 · Cited by 109
Alemohammad, H., Najafzadeh, B., Asadzadeh, Z., Baghbanzadeh, A., Ghorbaninezhad, F., Najafzadeh, A., Safarpour, H., Bernardini, R., Brunetti, O., Sonnessa, M., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112516 · Cited by 92
Myeloid-derived suppressor cells (MDSC): an important partner in cellular/tissue senescence
Salminen, A., Kauppinen, A., & Kaarniranta, K. (2018) · Biogerontology · doi:10.1007/s10522-018-9762-8 · Cited by 84
Fernandez, I. E., Greiffo, F. R., Frankenberger, M., Bandres, J., Heinzelmann, K., Neurohr, C., Hatz, R., Hartl, D., Behr, J., & Eickelberg, O. (2016) · European Respiratory Journal · doi:10.1183/13993003.01826-2015 · Cited by 75
Wang, Y., Hu, G.-F., & Wang, Z. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s136259 · Cited by 21
Self-citation
Metadata
- Authors
- Yu, J., Du, W., Yan, F., Wang, Y., Li, H., Cao, S., Yu, W., Shen, C., Liu, J., & Ren, X.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-04-01
- Volume
- 190
- Issue
- 7
- Pages
- 3783-3797
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2111762872
- Cited by
- 606
- References
- 48
- FWCI
- 19.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.